Cornelius A De Kruif

Title: Cornelius A De Kruif: Innovator in Rabies Virus Neutralization

Introduction

Cornelius A De Kruif is a notable inventor based in De Bilt, Netherlands. He has made significant contributions to the field of virology, particularly in the development of binding molecules that can neutralize the rabies virus. His work has implications for both diagnosis and treatment of rabies, a disease that poses serious health risks globally.

Latest Patents

Cornelius A De Kruif holds a patent for "Binding molecules capable of neutralizing rabies virus and uses thereof." This invention provides binding molecules that specifically target the rabies virus and are capable of neutralizing it. The patent also includes nucleic acid molecules encoding these binding molecules, compositions that comprise them, and methods for identifying or producing these molecules. The binding molecules can be utilized in the diagnosis, prophylaxis, and treatment of conditions resulting from rabies virus exposure, particularly in post-exposure prophylaxis scenarios.

Career Highlights

Cornelius A De Kruif is associated with Crucell Holland B.V., a company known for its innovative approaches in the biopharmaceutical sector. His work at Crucell has allowed him to focus on developing solutions that address critical health challenges, particularly those related to viral infections.

Collaborations

Throughout his career, Cornelius has collaborated with notable colleagues, including Alexander B H Bakker and Willem Egbert Marissen. These collaborations have likely contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Cornelius A De Kruif's contributions to the field of virology, particularly through his patent on rabies virus neutralization, highlight his role as an important innovator. His work not only advances scientific understanding but also has the potential to save lives through improved treatment options for rabies.